Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bone morphogenetic protein-2 + demineralized bone matrix** is a combination product used as a bone graft substitute to promote bone regeneration and repair. **Bone morphogenetic protein-2 (BMP-2)** is a recombinant protein that induces osteogenic differentiation, stimulating the formation of new bone tissue. **Demineralized bone matrix (DBM)** is processed allograft bone material from which the mineral content has been removed, retaining organic matrix proteins and endogenous growth factors with osteoinductive and osteoconductive properties. In this combination, DBM serves as a scaffold and carrier for BMP-2, providing a local environment for sustained release and action of BMP-2 at the defect site. This enhances bone healing compared to DBM or BMP-2 alone and mimics the natural bone regeneration process[1][3][4][5]. The combination is used in orthopedic and oral/maxillofacial procedures to treat bone defects and non-unions, and may serve as an alternative to autologous bone grafts[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bone morphogenetic protein-2 + demineralized bone matrix.